Commercial and Pipeline Insight: Opioids - Short acting and anti-abuse technologies set to fragment and grow the market

Abstract

Overview

Introduction

The opioid market is currently valued at $7.7 billion and is set to increase over the next 10 years at a CAGR of 2.4%. Despite this market being exclusively comprised of old genericized molecules, novel formulations and delivery methods have stimulated growth over the last 5 years. This growth is set to continue as current market players instigate lifecycle management strategies to retain value.

Scope

• Sales volume and value forecasts to 2017 of marketed brands, generics, and key late-stage pipeline drugs.
• Analysis of patient potential, unmet needs and clinical trial design in the opioid market.
• Overview of key marketed brands, late- and early-stage pipeline drugs.
• Identification of future market events that are expected to affect opioid revenues.

Highlights

Short-acting opioids represent good in-licensing opportunities for companies with large sales and marketing resources. This market is expected to triple in value over the next 10 years, driven by Cephalon' s Fentora for use in breakthrough pain, and supported by other new short-acting fentanyl formulations.

The long-acting opioid market was valued at over $3 billion in 2007, and is due to grow until the patent expiry of market leader OxyContin in 2011. After a short lived decline, market growth will be stimulated by the launch of anti-abuse formulations, a technical development anticipated to create a $1 billion market.

The topical market represents an opportunity for companies to enter a comparatively underserved market. Although Johnson and Johnson' s market leading Duragesic (fentanyl patch) has faced generic opposition since 2005, sales remain relatively strong due to brand strength and the lack of branded competition.

Reasons to Purchase

• Benchmark key late-stage pipeline opioids against current market leading brands.
• Assess region-specific (US, Japan, 5EU) sales forecasts of key late-stage pipeline drugs and marketed brands.
• Understand unmet needs and opportunities in the opioid market based on key opinion leader comments.